BioBioPha
China
Product Name: N-(3-(4-Fluorophenyl)propyl) -7-hydroxycoumarin-3-carboxamide
Price: ￥4250.0/5mg
Purity: 96.0%
Stocking Period: 10 Day
Contact: Xueping-Zheng

2136579-33-2

2136579-33-2 structure

Name: AKR1B10-IN-1
Chemical Name: AKR1B10-IN-1
CAS Number: 2136579-33-2
Molecular Formula: C₁₉H₁₆FNO₄
Molecular Weight: 341.33
Catalog: Signaling Pathways Metabolic Enzyme/Protease Aldose Reductase
Create Date: 2022-02-20 15:06:19
Modify Date: 2024-01-20 13:35:12
AKR1B10-IN-1 is a potent inhibitor of AKR1B10 (Aldo-Keto Reductase 1B10) with an IC50 of 3.5 nM. AKR1B10-IN-1 suppresses proliferation, metastasis, and Cisplatin (CDDP) resistance of lung cancer cells[1].

Name	AKR1B10-IN-1
Synonyms	N-(3-(4-Fluorophenyl)propyl) -7-hydroxycoumarin-3-carboxamide

Description	AKR1B10-IN-1 is a potent inhibitor of AKR1B10 (Aldo-Keto Reductase 1B10) with an IC50 of 3.5 nM. AKR1B10-IN-1 suppresses proliferation, metastasis, and Cisplatin (CDDP) resistance of lung cancer cells[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Metabolic Enzyme/Protease >> Aldose Reductase
Target	3.5 nM (AKR1B10); 277 nM (AKR1B1)[1]
In Vitro	AKR1B10-IN-1 (compound 4e) (0-20 μM; 96 hours) dose-dependently suppresses the growth of both A549 and A549/1B10 cells[1]. AKR1B10-IN-1 (compound 4e) (0-20 μM; 96 hours) completely suppresses increased cell proliferation by the overexpressing AKR1B10 as well as the endogenous protein[1]. AKR1B10-IN-1 (compound 4e) (0-40 μM; 26 hours; pretreatment with AKR1B10-IN-1 for 2 hours, then incubated with CDDP for 24 hours) decreases the cell viability of CDDP-R-A549 cells in a dose-dependent manner[1]. Cell Viability Assay[1] Cell Line: A549 cells, A549/1B10 cells (AKR1B10-stably overexpressing A549 cells) Concentration: 0, 10, 20 μM Incubation Time: 96 hours Result: Dose-dependently suppressed the growth of both A549 and A549/1B10 cells, and statistically significant at 20 μM. Cell Viability Assay[1] Cell Line: CDDP-resistance (cisplatin-resisitance) of A549 cells Concentration: 0, 10, 20, 40 μM Incubation Time: Pretreatment with AKR1B10-IN-1 for 2 hours, then incubated with CDDP for 24 hours Result: Decreased the cell viability of CDDP-R-A549 cells in a dose-dependent manner, and most obvious in the treatment of 40 μM.
References	[1]. Endo S, et al. Synthesis of Potent and Selective Inhibitors of Aldo-Keto Reductase 1B10 and Their Efficacy against Proliferation, Metastasis, and Cisplatin Resistance of Lung Cancer Cells [published correction appears in J Med Chem. 2018 Feb 8;61(3):1380]. J Med Chem. 2017;60(20):8441-8455.

Molecular Formula	C₁₉H₁₆FNO₄
Molecular Weight	341.33

2136579-33-2	1364683-67-9
407587-01-3	1933533-18-6
924296-18-4	877225-09-7
2366149-83-7	1207358-59-5
2055990-90-2	1364914-72-6
1158522-08-7	940364-43-2
37695-39-9	134104-43-1
131615-57-1	6906-52-1
930439-75-1	1018584-77-4
1805251-26-6	1594104-49-0